Genetic risk scores and number of autoantibodies in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 74, Issue 4, 2015, Pages 762-768

  Maehlen, Marthe T ^a,b   Olsen, Inge C ^a   Andreassen, Bettina K ^b   Viken, Marte K ^b   Jiang, Xia ^c   Alfredsson, Lars ^c   Källberg, Henrik ^c   Brynedal, Boel ^c   Kurreeman, Fina ^d   Daha, Nina ^d   Toes, Rene ^d   Zhernakova, Alexandra ^d,e   Gutierrez Achury, Javier ^e   De Bakker, Paul I W ^f   Martin, Javier ^g   Teruel, María ^g   Gonzalez Gay, Miguel A ^h   Rodríguez Rodríguez, Luis ⁱ   Balsa, Alejandro ^j   Uhlig, Till ^a   Kvien, Tore K ^a   Lie, Benedicte A ^b   more..

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c KAROLINSKA INSTITUTE   (Sweden)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^h HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

ⁱ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^j HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; HLA DRB1 ANTIGEN; RHEUMATOID FACTOR; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE;

ANTIBODY DETECTION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE PREDISPOSITION; EUROPE; FEMALE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC RISK SCORE; GENETIC VARIABILITY; GENOTYPE; HLA DRB1 GENE; HLA TYPING; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION GENETICS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; STANDARDIZATION; ALLELE; CASE CONTROL STUDY; CAUCASIAN; GENETICS; IMMUNOLOGY; RISK FACTOR;

ALLELES; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HLA-DRB1 CHAINS; HUMANS; MALE; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; RISK ASSESSMENT; RISK FACTORS;

EID: 84925605422     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204173     Document Type: Article

References (55)

1. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
2. Symmons DP, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol 2011;7:399-408.
3. Syversen SW, Gaarder PI, Goll GL, et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2008;67:212-17.
4. De RL, Peene I, Hoffman IE, et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 2004;63:1587-93.
5. Sellam J, Rouanet S, Hendel-Chavez H, et al. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2011;63:3692-701.
6. Van Der Woude D, Young A, Jayakumar K, et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum 2009;60:2262-71.
7. Chatzidionysiou K, Lie E, Nasonov E, et al. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis 2012;71:374-7.
8. Matsui T, Shimada K, Ozawa N, et al. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis. J Rheumatol 2006;33:2390-7.
9. Nielen MM, Van SD, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
10. Rantapaa-Dahlqvist S, De Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
11. MacGregor AJ, Snieder H, Rigby AS, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000;43:30-7.
12. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009;373:659-72.
13. Eyre S, Bowes J, Diogo D, et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 2012;44:1336-40.
14. Raychaudhuri S, Thomson BP, Remmers EF, et al. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet 2009;41:1313-18.
15. Raychaudhuri S, Remmers EF, Lee AT, et al. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet 2008;40:1216-23.
16. Daha NA, Toes RE. Rheumatoid arthritis: Are ACPA-positive and ACPA-negative RA the same disease? Nat Rev Rheumatol 2011;7:202-3.
17. Kurko J, Besenyei T, Laki J, et al. Genetics of rheumatoid arthritis-a comprehensive review. Clin Rev Allergy Immunol 2013;45:170-9.
18. ∗0401 MHC class II molecule. J Immunol 2003;171:538-41.
19. Huizinga TW, Amos CI, Van Der Helm-van Mil AH, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 2005;52:3433-8.
20. Padyukov L, Silva C, Stolt P, et al. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 2004;50:3085-92.
21. Karlson EW, Chibnik LB, Kraft P, et al. Cumulative association of 22 genetic variants with seropositive rheumatoid arthritis risk. Ann Rheum Dis 2010;69:1077-85.
22. Chibnik LB, Keenan BT, Cui J, et al. Genetic risk score predicting risk of rheumatoid arthritis phenotypes and age of symptom onset. PLoS One 2011;6:e24380.
23. Kurreeman F, Liao K, Chibnik L, et al. Genetic basis of autoantibody positive and negative rheumatoid arthritis risk in a multi-ethnic cohort derived from electronic health records. Am J Hum Genet 2011;88:57-69.
24. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
25. Maehlen MT, Provan SA, De Rooy DP, et al. Associations between APOE Genotypes and Disease Susceptibility, Joint Damage and Lipid Levels in Patients with Rheumatoid Arthritis. PLoS One 2013;8:e60970.
26. Bengtsson C, Berglund A, Serra ML, et al. Non-participation in EIRA: a population-based case-control study of rheumatoid arthritis. Scand J Rheumatol 2010;39:344-6.
27. Stolt P, Bengtsson C, Nordmark B, et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis 2003;62:835-41.
28. Van AJ, Van Bilsen JH, Allaart CF, et al. The Leiden Early Arthritis Clinic. Clin Exp Rheumatol 2003;21:S100-5.
29. Trynka G, Hunt KA, Bockett NA, et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat Genet 2011;43:1193-201.
30. Van Der Linden MP, Van Der Woude D, Ioan-Facsinay A, et al. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 2009;60:2232-41.
31. Gregersen PK, Amos CI, Lee AT, et al. REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. Nat Genet 2009;41:820-3.
32. Plant D, Flynn E, Mbarek H, et al. Investigation of potential non-HLA rheumatoid arthritis susceptibility loci in a European cohort increases the evidence for nine markers. Ann Rheum Dis 2010;69:1548-53.
33. Plenge RM, Seielstad M, Padyukov L, et al. TRAF1-C5 as a risk locus for rheumatoid arthritis-a genomewide study. N Engl J Med 2007;357:1199-209.
34. Plenge RM, Cotsapas C, Davies L, et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 2007;39:1477-82.
35. Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007;357:977-86.
36. Stahl EA, Raychaudhuri S, Remmers EF, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 2010;42:508-14.
37. Zhernakova A, Stahl EA, Trynka G, et al. Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. PLoS Genet 2011;7:e1002004.
38. ∗1301: a meta-analysis of HLA-DRB1 associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in four European populations. Arthritis Rheum 2010;62:1236-45.
39. Raychaudhuri S, Sandor C, Stahl EA, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet 2012;44:291-6.
40. Garcia-Bermudez M, Gonzalez-Juanatey C, Lopez-Mejias R, et al. Study of association of CD40-CD154 gene polymorphisms with disease susceptibility and cardiovascular risk in Spanish rheumatoid arthritis patients. PLoS One 2012;7:e49214.
41. Nordang GB, Flåm ST, Maehlen MT, et al. HLA-C alleles confer risk for anticitrullinated peptide antibody-positive rheumatoid arthritis independent of HLA-DRB1 alleles. Rheumatology (Oxford) 2013;52:1973-82.
42. Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978;8:283-98.
43. Jonsson T, Thorsteinsson J, Valdimarsson H. Elevation of only one rheumatoid factor isotype is not associated with increased prevalence of rheumatoid arthritis-a population based study. Scand J Rheumatol 2000;29:190-1.
44. Swedler W, Wallman J, Froelich CJ, et al. Routine measurement of IgM, IgG, and IgA rheumatoid factors: high sensitivity, specificity, and predictive value for rheumatoid arthritis. J Rheumatol 1997;24:1037-44.
45. Van De Stadt LA, Van Der Horst AR, De Koning MH, et al. The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. Ann Rheum Dis 2011;70:128-33.
46. Van Der Woude D, Rantapaa-Dahlqvist S, Ioan-Facsinay A, et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis 2010;69:1554-61.
47. Scherer HU, Van Der Woude D, Ioan-Facsinay A, et al. Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum 2010;62:1620-9.
48. Van Der Woude D, Houwing-Duistermaat JJ, Toes RE, et al. Quantitative heritability of anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis. Arthritis Rheum 2009;60:916-23.
49. Verpoort KN, Van Gaalen FA, Van Der Helm-van Mil AH, et al. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis Rheum 2005;52:3058-62.
50. Irigoyen P, Lee AT, Wener MH, et al. Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles. Arthritis Rheum 2005;52:3813-18.
51. Padyukov L, Seielstad M, Ong RT, et al. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis 2011;70:259-65.
52. De Jager PL, Chibnik LB, Cui J, et al. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol 2009;8:1111-19.
53. Hu P, Muise AM, Xing X, et al. Association between a multi-locus genetic risk score and inflammatory bowel disease. Bioinform Biol Insights 2013;7:143-52.
54. Talmud PJ, Hingorani AD, Cooper JA, et al. Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study. BMJ 2010;340:b4838.
55. Lambert PC, Sutton AJ, Abrams KR, et al. A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. J Clin Epidemiol 2002;55:86-94.